| Hazard Information | Back Directory | [Description]
YPC-22026 is a novel inducer of tumor regression accompanied by the suppression of ZNF143-regulated genes in a mouse xenograft model. | [Uses]
YPC-22026 is a zinc-finger protein 143 (ZNF143) inhibitor with an IC50 value of 9.0 μM. YPC-22026 is a potent tumor regression inducer. YPC-22026 exhibits anti‐tumor activities[1]. | [in vivo]
YPC‐22026 (50-100 mg/kg; i.p; on days 1, 2, 3, 8, 9, 12, and 16) significantly inhibits the growth of tumors in the HCT116 xenograft model[1].
In the PC‐3 xenograft model, YPC‐22026 (75 mg/kg; ip) significantly decreases in the intratumoral expression levels of all ZNF143 target genes, RAD51, PLK1, and Survivin[1]. | Animal Model: | Six‐week‐old male BALB/c nude mice injected with HCT116 cells[1] | | Dosage: | 50 mg/kg and 100 mg/kg | | Administration: | i.p; on days 1, 2, 3, 8, 9, 12, and 16 (50 mg/kg ); on days 1, 2, 3, 12, and 16 (100 mg/kg) | | Result: | Significantly inhibited the growth of tumors. |
| [References]
[1] Hirotaka Haibara, et al. YPC-21661 and YPC-22026, novel small molecules, inhibit ZNF143 activity in vitro and in vivo. Cancer Sci. 2017 May;108(5):1042-1048. DOI:10.1111/cas.13199 |
|
|